ContributorsPublishersAdvertisers

Oral Fluoropyrimidine Prolongs Survival as Adjuvant Treatment for Biliary Tract Cancer

targetedonc.com
 2022-01-21

Cover picture for the articleIn a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery. Adjuvant oral fluoropyrimidine derivative S-1 is now a recommended standard of care for patients with biliary tract cancer after the agent prolonged overall survival compared with surgery...

www.targetedonc.com

Comments / 0

Comments / 0